AGC Biologics, a global biopharmaceutical CDMO has entered a collaboration with W.L. Gore & Associates (Gore) that leverages Protein A affinity purification technology from Gore and the AGC’s contract development and manufacturing services. 
 
The companies aim to improve downstream purification processes through increased productivity of the Protein A step, enabling a full single-use downstream process, which can eliminate column bioburden from storage, reduce manufacturing footprint, and help lower costs for clinical manufacturing and select scale commercial manufacturing.  
 
The collaboration includes the family of GORE Protein Capture Devices with Protein A, which improves productivity in Protein A affinity purification, and provides high binding capacity at short residence times, alongside AGC Biologics’ mAb-based CDMO services. The joint offering is available across various sites in the AGC Biologics’ network.  
 
“This is a notable example of how our technology can support antibody-based therapies coming to market by addressing bottlenecks and boosting productivity,” said William Barrett, Ph.D., Product Specialist, for GORE PharmBIO. “Our portfolio of GORE Protein A Capture Devices, with a unique expanded polytetrafluoroethylene (ePTFE) membrane, offers a scalable solution and we are thrilled to work with ACG Biologics so customers can reach their next clinical or commercial milestones.” 
 
“Investments in new technologies like the GORE Protein Capture Device are important to meet our clients’ needs and address the changes in the monoclonal antibody market,” said Kasper Møller, Chief Technical Officer of AGC Biologics. “We are excited to offer this new technology for GMP manufacturing at relevant scales throughout our manufacturing network.”